COMP <GO>
ARQT vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ARQT 5
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $32.07 (+0.31%) • MKT CAP: $4.02B
roic
-3.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | 74.80% | +15.40 | ARQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -3.00% | 20.70% | -23.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 3.42% | -3.58 | MRK | /fcf-yield <GO> |
| Operating Margin | -3.30% | 34.30% | -37.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -4.30% | 28.10% | -32.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 1.30% | +90.00 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 5.19 | +2.59 | ARQT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 56.9 | +9.48 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 18.4x | +5.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.02B | $361.02B | -$357.00B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | MRK REV | ARQT GROSS % | MRK GROSS % | ARQT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $65.01B | 90.2% | 74.8% | -$6.3M | $12.36B |
| FY 2024 | $196.5M | $64.17B | 90.3% | 76.3% | -$112.3M | $18.10B |
| FY 2023 | $59.6M | $60.12B | 44.0% | 44.0% | -$249.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
MRK // BETA 0.92